Raymond James Financial
DMAC icon

Raymond James Financial’s DiaMedica Therapeutics DMAC Stock Holding History

Raymond James Financial’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$107K Sell
15,791
-10
-0.1% -$79 ﹤0.01% 5020
2025
Q4 		$126K Sell
15,801
-20,700
-57% -$155K ﹤0.01% 4888
2025
Q3 		$251K Buy
36,501
+20,734
+132% +$112K ﹤0.01% 4510
2025
Q2 		$61.5K Buy
15,767
+100
+0.6% +$390 ﹤0.01% 5100
2025
Q1 		$59.4K Buy
15,667
+400
+3% +$2.29K ﹤0.01% 4623
2024
Q4 		$82.9K Buy
+15,267
New +$72K ﹤0.01% 4552

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Raymond James Financial's DMAC Position: Q1 2026 in Review

Raymond James Financial reduced its DiaMedica Therapeutics (DMAC) stake by 0.06% in Q1 2026, selling an estimated $79 and leaving 15,791 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #5020.

Raymond James Financial first reported a position in DMAC in Q4 2024 and has held it in 6 quarters since. The position peaked at $251K in Q3 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Raymond James Financial held 15,791 shares of DiaMedica Therapeutics worth $107K as of Q1 2026.
  • Raymond James Financial sold 10 DiaMedica Therapeutics shares in Q1 2026, an estimated $79.
  • DiaMedica Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5020 holding.
  • Raymond James Financial first reported a position in DiaMedica Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's DiaMedica Therapeutics position peaked at $251K in Q3 2025.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.